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Purpose: Primary congenital glaucoma (PCG) is an autosomal recessive eye disorder that is postulated to result from
developmental  defects  in  the  anterior  eye  segment.  Mutations  in  the  cytochrome  P4501B1  (CYP1B1)  gene  are  a
predominant cause of congenital glaucoma. In this study we identify CYP1B1 mutations in PCG patients.
Methods: Twenty-three unrelated PCG patients and 50 healthy controls were enrolled in the study. CYP1B1 was screened
for mutations by PCR and DNA sequencing.
Results: DNA sequencing revealed a total of 15 mutations. Out of these, four (p.I94X, p.H279D, p.Q340H, and p.K433K)
were novel mutations and five were known pathogenic mutations. Five coding single nucleotide polymorphisms and one
intronic single nucleotide polymorphism (rs2617266) were also found. Truncating mutations (p.I94X and p.R355X) were
associated with the most severe disease phenotype. It is possible that patients with two null alleles with no catalytic activity
may present with a more severe phenotype of the disease compared to patients with one null allele (heterozygous). The
disease phenotype of patients with CYP1B1 mutations was more severe compared with the clinical phenotype of patients
negative for CYP1B1 mutations.
Conclusion: Mutations in CYP1B1 are a major cause for PCG in our patients. Identifying mutations in subjects at risk of
developing glaucoma, particularly among relatives of PCG patients, is of clinical significance. These developments may
help in reducing the disease frequency in familial cases. Such studies will be of benefit in the identification of pathogenic
mutations in different populations and will enable us to develop simple and rapid diagnostic tests for analyzing such cases.
Primary congenital glaucoma (PCG; OMIM 231300) is
an autosomal recessive disorder of the eye. In this disease the
trabecular meshwork (TM) and anterior chamber of the eye
are affected, leading to impairment in the aqueous drainage,
increased intraocular pressure (IOP), and optic nerve damage.
PCG occurs during the neonatal or early infantile period [1].
The term PCG is reserved for those cases in which the only
anatomic  defect  observed  is  isolated  trabeculodysgenesis.
This  increased  IOP  results  in  ocular  enlargement
(buphthalmos),  corneal  clouding,  and  rapid  optic  nerve
cupping. Progressive degeneration of the retinal ganglion cells
(RGCs) results in the characteristic optic nerve atrophy and
visual field defects found in glaucoma. Most cases of PCG are
sporadic, but familial cases have also been reported. PCG is
the most common type of pediatric glaucoma and accounts for
55% of such cases. Its expression and penetrance vary from
40–100%.  Its  incidence  varies  substantially  from  one
population to another. It is estimated to occur in 1 in 10,000
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births in Europe and 1 in 3,300 births in Andhra Pradesh, India
[2,3].
Recently a putative PCG locus, GLC3A, was linked to
markers on the short arm of chromosome 2 in 11 Turkish
families [4]. Six other families did not show linkage to this
locus, suggesting locus heterogeneity for this disease. Another
PCG locus, GLC3B, was localized on chromosome 1p36 in
some families but did not show linkage to chromosome 2
markers  [5].  Other  subsets  of  families  that  did  not  show
linkage to these two loci provide evidence for at least a third
of the unmapped loci [5]. Recently Stoilov et al. [6] identified
three  different  mutations  in  the  cytochrome  P4501B1
(CYP1B1) gene in five unrelated Turkish families in which
the disease had been linked to the 2p21 locus [6]. Even though
three different loci have been mapped for PCG, mutations in
CYP1B1 (GLC3A) are the most predominant cause of disease
and  are  reported  in  various  ethnic  backgrounds  [6-15].
Further,  it  is  estimated  that  all  the  known  loci/genes  of
glaucoma account for a minority of the total cases of glaucoma
[4,5], and hence many other genes remain to be identified.
CYP1B1 is located on chromosome 2 and consists of three
exons and two introns. The coding region of CYP1B1 starts at
the 5′ end of exon 2 and ends within exon 3. It codes for a 543-
amino acid protein and is expressed in the ocular tissues, such
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2926as  the  anterior  chamber,  and  in  several  nonocular  tissues
[16].  CYP1B1  is  a  member  of  the  cytochrome  P450
superfamily  of  drug-metabolizing  enzymes.  It  catalyzes
several oxidative reactions, some of which are biosynthetic,
producing necessary hormones or compounds of intermediary
metabolism in most living organisms and substrates, including
many xenobiotics, vitamins, and steroids [17]. CYP1B1 also
metabolizes vitamin A in two steps to all-trans-retinal and all-
trans-retinoic  acid.  The  latter  is  a  potent  morphogen  and
regulates  in  utero  development  of  tissue  growth  and
differentiation. CYP1B1 is involved in the metabolism of
endogenous and exogenous substrates that take part in early
ocular  differentiation  [18-20].  In  the  present  study  we
screened  all  coding  exons  of  CYP1B1  in  23  unrelated
congenital glaucoma patients.
METHODS
Clinical evaluation and patient selection: Primary congenital
glaucoma  cases  presenting  at  the  Dr.  R.  P.  Centre  for
Ophthalmic  Sciences  (AIIMS,  New  Delhi,  India),  were
enrolled for this study. Six patients were female and 17 were
male. Mean age of presentation was 15.17 months (range 1.5
–  132  months).  After  ethical  approval  of  the  Institutional
Review Board (IRB00006862; All India Institute of Medical
Sciences, New Delhi, India), 23 PCG cases were enrolled in
this study. The diagnosis involved clinical ocular and systemic
examination. Inclusion criteria of the patients were increased
corneal diameter (>12.0 mm) and raised IOP (>21 mmHg)
with presence/absence of Haab’s striae and optic disc changes
(where examination was possible). Symptoms of epiphora and
photophobia were the additional inclusion factors. The age of
onset ranged from birth to 3 years. Detailed family histories
up to three generations were taken, and pedigree charts were
constructed.  The  history  of  ocular  or  other  hereditary
disorders was recorded. Glaucoma cases other than PCG were
excluded.  Fifty  ethnically  matched  normal  individuals
without  any  ocular  disorders  were  enrolled  as  controls.
Peripheral blood samples were collected from patients and
controls  by  venipuncture  after  informed  consent.  Blood
samples were collected in EDTA vaccutainer and stored in -80
°C until DNA isolation.
Mutation screening and sequence analysis: Genomic DNA
was isolated from peripheral blood by the phenol chloroform
method.  The  entire  coding  region,  including  exon–intron
boundaries  of  CYP1B1,  from  patients  and  controls  was
amplified and screened for mutations by using three sets of
overlapping primers (Table 1) [7,21]. The primers used were
set I (1F–1R, 786 bp) [12], set II (2F–2R, 787 bp) [13], and
set III (3F–3R, 885 bp) [12]. PCR amplifications for primer
sets I and II were performed in a 40 µl volume containing 1.0
µl of 20 µM stock solution for each primer, 100 ng of genomic
DNA, 1 unit of Taq polymerase (Banglore Genei), 0.1 mM of
each dNTP, 4 µl of 10X PCR buffer (with 15 mM MgCl2) and
4 µl of dimethyl sulphoxide (Sigma), by means of 35 cycles
of amplification, each consisting of 30 s denaturation at 94
°C, 30 s annealing at 56 °C and 1 min extension at 72 °C [12],
while conditions for set III were initial denaturation at 94 °C
for 3 min followed by 30 cycles each at 94 °C for 30 s, 60 °C
for 30 s, and 72 °C for 1 min.
Amplified PCR products were purified using a gel/PCR
DNA  fragments  extraction  kit  (number  DF100;  Geneaid
Biotech Ltd., Sijhih City, Taiwan). Purified PCR products
were sent for sequencing to MCLAB (Molecular Cloning
Laboratories,  South  San  Francisco,  CA).  DNA  sequences
were  analyzed  against  the  CYP1B1  reference  sequence
ENSG00000138061  using  ClustalW2  (multiple  sequence
alignment program for DNA; European Molecular Biology
Laboratory  (EMBL)  –  European  Bioinformatics  Institute
(EBI)).
Computational  assessment  of  missense  mutations:  Two
homology-based  programs  PolyPhen  (polymorphism
phenotyping; Division of Genetics, Department of Medicine,
Brigham and Women’s Hospital/Harvard Medical School,
Boston, MA) and SIFT (sorting intolerant from tolerant; the
J. Craig Venter Institute Rockville, MD and La Jolla, CA)
were  used  to  predict  the  functional  impact  of  missense
changes  identified  in  this  study.  PolyPhen  structurally
analyzes an amino acid polymorphism and predicts whether
that amino acid change is likely to be deleterious to protein
function [22-24]. The prediction is based on the position-
specific  independent  counts  (PSIC)  score  derived  from
multiple  sequence  alignments  of  observations.  PolyPhen
scores  of  >2.0  indicate  the  polymorphism  is  probably
damaging to protein function. Scores of 1.5–2.0 are possibly
damaging, and scores of <1.5 are likely benign. SIFT is a
sequence  homology-based  tool  that  sorts  intolerant  from
TABLE 1. THE PRIMERS USED FOR PCR AMPLIFICATION.
Primer sequence Product size (bp)
1F-5′-TCTCCAGAGAGTCAGCTCCG-3′ 786
1R-5′-GGGTCGTCGTGGCTGTAG-3′  
2F-5′-ATGGCTTTCGGCCACTACT-3′ 787
2R-5′-GATCTTGGTTTTGAGGGGTG-3′  
3F-5′-TCCCAGAAATATTAATTTAGTCACTG-3′ 885
3R-5′-TATGGAGCACACCTCACCTG-3′  
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2927tolerant  amino  acid  substitutions  and  predicts  whether  an
amino acid substitution in a protein will have a phenotypic
effect  [25-28].  SIFT  is  based  on  the  premise  that  protein
evolution  is  correlated  with  protein  function.  Positions
important for function should be conserved in an alignment
of the protein family, whereas unimportant positions should
appear diverse in an alignment. Positions with normalized
probabilities <0.05 are predicted to be deleterious and those
≥0.05 are predicted to be tolerated.
RESULTS
All cases were found to be sporadic in origin. A total of 15
nucleotide changes were observed in this study. Out of these,
five  were  previously  reported  coding  single  nucleotide
polymorphisms (SNPs) and one was already reported as an
intronic  SNP;  five  were  known  pathogenic  CYP1B1
mutations.  Four  novel  nucleotide  changes  (two
nonsynonymous,  one  frameshift,  and  one  synonymous
mutation)  were  also  found  in  this  study.  Details  of  all
nucleotide changes are presented below.
Identification of four novel mutations:
Isoleucine94stop (p.I94X) mutation—In this mutation
a single base guanine (G) deletion (Figure 1) was observed at
genomic position 38302285, coding nucleotide number c.247.
This caused a frameshift after codon 82 and introduced a stop
codon (TAG) at position 94 in the protein. This mutation
produced a truncated CYP1B1 protein of 93 amino acids. This
change was identified as a homozygous mutation in the patient
(P55).
Histidine279aspartic  acid  (p.H279D)  mutation—In
this mutation a single base cytosine (C) was replaced by G
(Figure 2) at genomic position 38301697, coding nucleotide
Figure  1.  DNA  sequence  chromatogram  of  CYP1B1  exon  2
equivalent to codon 81–85. A: The reference sequence derived from
control is shown. B: Sequence derived from congenital glaucoma
patient P55 shows the homozygous deletion of G at c.247, which
caused a p.asp83thrfsX12 (p.I94X) mutation.
number c.835. This resulted in a codon change from CAC to
GAC and an amino acid change from histidine to aspartic acid
(p.H279D),  a  nonsynonymous  mutation  in  the  CYP1B1
protein. This mutation was identified in one patient (P61) and
was heterozygous.
Glutamine340histidine (p.Q340H) mutation—In this
mutation a single base G was replaced by thymine (T) (Figure
3) at genomic position 38301512, coding nucleotide number
c.1020. This resulted in a codon change from CAG to CAT
and  an  amino  acid  change  from  glutamine  to  histidine
(p.Q340H),  a  nonsynonymous  mutation  in  the  CYP1B1
protein. This mutation was identified in one patient (P56) and
was heterozygous and present with the p.R390H mutation in
this patient.
Lysine433lysine  (p.K433K)  mutation—In  this
mutation  a  single  base  G  was  replaced  with  adenine  (A)
(Figure 4) at genomic position 38298198, coding nucleotide
number c.1299. This resulted in a codon change from AAG
to AAA and resulted in no amino acid change (lysine). This
was a neutral mutation (p.K433K) in patient P69.
All four novel mutations p.I94X, p.H279D, p.Q340H,
and p.K433K have been registered in GenBank with accession
numbers  GQ925803,  GQ925804,  GQ925805,  and
GQ925806, respectively.
Other previously reported pathogenic CYP1B1 mutations:
Glutamic  acid229lysine  (p.E229K)  mutation—This
mutation resulted in G being replaced with A at genomic
position 38301847 (rs57865060), coding nucleotide number
c.685. This resulted in a codon change from GAA to AAA and
an amino acid change from glutamic acid to lysine (p.E229K),
a  nonsynonymous  mutation  in  the  CYP1B1  protein.  This
change was found in one patient (P65) and was heterozygous.
Figure  2.  DNA  sequence  chromatogram  of  CYP1B1  exon  2
equivalent to codon 277–280.  A: The reference sequence derived
from  control  is  shown.  B:  Sequence  derived  from  congenital
glaucoma  patient  P55  shows  heterozygous  c.835C>G,  which
predicts a codon change of CAC>GAC and a p.H279D mutation.
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2928Arginine355stop  (p.A355X)  mutation—In  this
mutation a single base C was replaced by T (Figure 5) at
genomic  position  38298434,  coding  nucleotide  number  c.
1063. This resulted in a codon change from CGA to TGA
(p.R355X), a nonsense mutation in the CYP1B1 protein. This
resulted in a truncated CYP1B1 protein of 355 amino acids.
The  p.R355X  mutation  was  described  only  once  in  the
literature [29]. This change was homozygous in one patient
(P70).
Figure  3.  DNA  sequence  chromatogram  of  CYP1B1  exon  2
equivalent to codon 339-342. A: The reference sequence derived
from  control  is  shown.  B:  Sequence  derived  from  congenital
glaucoma  patient  P56  shows  heterozygous  c.1020G>T  change,
which  predicts  a  codon  change  CAG>CAT  and  heterozygous
p.Q340H mutation.
Figure  4.  DNA  sequence  chromatogram  of  CYP1B1  exon  3
equivalent to codon 431-434. A: The reference sequence derived
from  control  is  shown.  B:  Sequence  derived  from  congenital
glaucoma  patient  P69  shows  heterozygous  c.1294C>G  and
heterozygous c.1299G>A, which predicts codon change CTG>GTG
and  AAG>AAA  and  heterozygous  p.L432V  and  p.K433K
mutations, respectively.
Arginine368histidine  (p.R368H)  mutation—In  this
mutation  a  single  base  G  was  replaced  by  A  at  genomic
position 38298394 (rs28936414), coding nucleotide number
c.1103. This resulted in a codon change from CGT to CAT
and  an  amino  acid  change  from  arginine  to  histidine
(p.R368H),  a  nonsynonymous  mutation.  This  change  was
homozygous in one patient (P68).
Arginine390cysteine  (p.R390C)  mutation— In  this
mutation  a  single  base  C  was  replaced  by  T  at  genomic
position 38298329 (rs56010818), coding nucleotide number
c.1168. This resulted in a codon change from CGC to TGC
and  an  amino  acid  change  from  arginine  to  cysteine
(p.R390C), a nonsynonymous mutation. This mutation was
identified in one patient (P64) and was heterozygous.
Arginine390histidine  (p.R390H)  mutation—In  this
mutation a single base G was replaced by A (Figure 6) at
genomic  position  38298328,  coding  nucleotide  number  c.
1169. This resulted in a codon change from CGC to CAC and
an amino acid change from arginine to histidine (p.R390H), a
nonsynonymous mutation. This mutation was identified in
one patient (P56) and was heterozygous.
Nonpathogenic CYP1B1 single nucleotide polymorphisms:
In addition to these pathogenic mutations, six previously
reported single nucleotide polymorphisms [8] were identified
in a less conserved region of the CYP1B1 protein. Details of
these polymorphisms are provided below.
Cytisine (C) to thymine (T) change in intron 1—In this
mutation, C was replaced by T at genomic position 38302544,
nucleotide position 780 in CYP1B1 (rs2617266) in intron I.
This was observed in 13 patients but was absent in controls.
Figure  5.  DNA  sequence  chromatogram  of  CYP1B1  exon  3
equivalent to codon 353-356.  A: The reference sequence derived
from  control  is  shown.  B:  Sequence  derived  from  congenital
glaucoma  patient  P70  shows  homozygous  c.1063C>T,  which
predicts  a  codon  change  CGA>TGA  and  p.R355X  nonsense
mutation.
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2929Arginine48glycine (p.R48G)—In this mutation, C was
replaced  by  guanine  (G)  at  genomic  position  38302390
(rs10012), coding nucleotide number c.142. This resulted in
a codon change from CGG to GGG and an amino acid change
from  arginine  to  glycine  (p.R48G),  a  nonsynonymous
mutation in the CYP1B1 protein. This change was also present
in controls.
Alanine119serine (p.A119S)—In this mutation G was
replaced by T at genomic position 38302177 (rs1056827),
coding nucleotide number c.355. This resulted in a codon
change from GCC to TCC and an amino acid change from
alanine to lysine (p.A119S), a nonsynonymous mutation in
the CYP1B1 protein. This change was found in patients P55
and P73 but absent in controls.
Leucine432valine (p.L432V)—In this mutation a single
base C was replaced by G at genomic position 38298203
(rs1056836), coding nucleotide number c.1294. This resulted
in a codon change from CTG to GTG and an amino acid
change from leucine to valine (p.L432V), a nonsynonymous
mutation in the CYP1B1 protein. This mutation was identified
in four patients; it was homozygous in three patients (P52,
P55, and P68) and heterozygous in one patient (P69) and was
also present in controls.
Aspartic  acid449aspartic  acid  (p.D449D)—In  this
mutation  a  single  base  T  was  replaced  by  C  at  genomic
position 38298150 (rs1056837), nucleotide position 5174 in
the gene, coding nucleotide number c.1347. This resulted in
a codon change from GAT to GAC and no change in the amino
acid (aspartic acid) (p.D449D), a synonymous mutation in the
CYP1B1 protein. This mutation was identified in 20 patients
and was homozygous in all. This change was also present in
controls.
Figure  6.  DNA  sequence  chromatogram  of  CYP1B1  exon  3
equivalent to codon 388-391. A: The reference sequence derived
from  control  is  shown.  B:  Sequence  derived  from  congenital
glaucoma  patient  P56  shows  homozygous  c.11169G>A,  which
predicts a codon change CGC>CAC and p.R390H mutation.
Asparagine453serine  (p.N453S)—In  this  mutation  a
single  base  A  was  replaced  by  G  at  genomic  position
38298139  (rs1800440),  coding  nucleotide  number  c.1358.
This resulted in a codon change from AAC to AGC and an
amino acid change from asparagine to serine (p.N453S), a
nonsynonymous  mutation  in  the  CYP1B1  protein.  The
p.N453S mutation was present in two patients (P51 and P62)
but absent in controls.
The clinical manifestations of PCG patients have been
tabulated  (Table  2),  and  the  CYP1B1  sequence  variants
identified in the various studies to date have been summarized
(Table 3). The clinical phenotype of the cases with pathogenic
CYP1B1  mutations  was  more  severe  compared  to  cases
without CYP1B1 mutations. The mean IOP of cases with
pathogenic CYP1B1 mutations was 30.21 mmHg compared
to 23.96 mmHg in mutation-negative cases; the difference is
significant (p value <0.005). The mean corneal diameter in
patients without the CYP1B1 mutations was 12.625×12.181
mm (left eye) and 12.406×12.781 mm (right eye), whereas it
was  13.833×13.750  mm  (left  eye)  and  13.416×15.50  mm
(right eye) in mutation-negative cases. Haab’s striae were
present in two cases (P56 and P61), which were positive for
the CYP1B1 mutations.
DISCUSSION
Structural/functional implications of mutations:
p.I94X mutation—In the isoleucine94stop mutation (p.
194X)  mutation  a  truncated  protein  of  93  amino  acids  is
produced in which only the first 82 amino acids are the same
as the wild-type CYP1B1 protein (Figure 7). This truncated
protein lacks all functional domains of the CYP1B1 protein
and is a nonfunctional protein [6,21,29,30].
p.H279D mutation—This histidine residue lies in the
carboxyl terminal of the G helix in the CYP1B1 protein.
Replacement of an aromatic, weak basic, amino acid histidine
whose charge state depends upon its protonation state with an
aliphatic, strong acidic, and negatively charged aspartic acid
at this locus. This in turn affects the local charge distribution,
and hence the structure of the protein is disturbed. Histidine
is conserved at this locus in the CYP1A1 protein from 12
different species (Figure 8) and in the CYP1B1 protein from
seven different species (Figure 9) analyzed, suggesting that
histidine performs some important functions at this locus. No
other known pathogenic mutation was present in the patient
(P61),  and  the  PSIC  score  of  this  mutation  was  2.628,
indicating that this change is probably damaging to the protein
function.  The  SIFT  score  of  p.H279D  was  0.00  and  is
predicted to be deleterious for the protein function.
p.Q340H mutation—This glutamine residue lies in the
carboxyl  terminal  of  the  I  helix.  Replacement  of  a  polar
uncharged amino acid (glutamine) with a weak basic amino
acid (histidine) may or may not alter the structure/function of
the protein. Glutamine is not conserved at this locus in the
CYP1A1 protein from 12 different species analyzed (Figure
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29328)  but  is  conserved  in  the  CYP1B1  protein  from  seven
different species analyzed (Figure 9). The PSIC score of this
mutation was 0.276, indicating that this change is benign to
protein function. The SIFT score of p.Q340H was 0.05 and is
predicted  to  be  tolerated.  The  patient  with  the  p.Q340H
mutation also had a known pathogenic CYP1B1 mutation
(p.R390H) and had a PSIC score of 2.799 and a SIFT score of
0.00. The p.R390H mutation has previously been reported
[21] to adversely affect or damage protein function.
p.E229K mutation—The p.E229k mutation occurred in
the carboxyl terminal of the F helix in the vicinity of the
substrate-binding region in the CYP1B1 protein. Substitution
of E to K leads to a change from a negatively charged residue
to a positively charged side chain, and this in turn affects the
local charge distribution. This disturbs an important cluster of
salt bridges. In wild-type CYP1B1 protein, R-194::E-229,
R-194::D-333, and D-333::K-512 form a triangle of ionic
bond interactions, holding the I helix with the F helix and β-
strand S3.2. As a result of this mutation, the R-194::E-229
interaction is lost, which has the potential to destabilize the
other ionic interactions in the protein [30]. The SIFT score of
the  p.E229K  mutation  was  0.01  and  is  predicted  to  be
deleterious for the protein function. The CYP1B1 protein with
the  p.E229K  mutation  shows  20–40%  enzymatic  activity
compared to the wild-type CYP1B1 protein [31].
p.R355X  mutation—In  the  p.R355X  mutation,  a
truncated protein of 354 amino acids is produced (Figure 7).
The  arginine  residue  at  position  355  lies  in  the  carboxyl
terminal of the J helix, carboyxl terminal of the J helix is
involved in the functionally important heme-binding domain.
This truncating mutation results in a loss of the heme-binding
domain and a functionally inactive protein [6,21,29,30].
p.R368H mutation—This arginine residue lies between
the J and K helix in an exposed loop [8,15]. In this mutation
the positively charged amino acid arginine is replaced by
histidine whose charge state depends upon its protonation
state.  Consequences  of  this  change  are  not  immediately
apparent. In the wild type, arginine at position 368 interacts
with G-365, D-367, V-363, and D-374. Because of the R368H
mutation,  interaction  between  D-367  and  D-374  are
weakened.  The  PSIC  score  of  this  mutation  was  2.653,
indicating that this change is probably damaging to protein
function.  The  SIFT  score  of  p.R368H  was  0.00  and  is
predicted  to  be  deleterious  for  the  protein  function.  How
p.R368H affects the conformation and functionality of the
protein is still not clear [31].
p.R390H/C mutation—This arginine residue is located
in the conserved α helix K [8]. It forms the consensus sequence
GluXXArg, which is conserved among all members of the
cytochrome P450 superfamily [21]. Arg390 and Glu387 are
one helical turn apart and are predicted to form a salt bridge.
The parallel orientation of their side chains is more transparent
in the three-dimensional model. Conservation of this motif
indicates that presence of arginine at this position is essential
for the normal function of the P450 molecule. The PSIC scores
of p.R390C and p.R390H were 3.474 and 2.799, respectively,
Figure  7.  Amino  acid  sequence  of
CYP1B1  protein.  A:  Wild-type
CYP1B1  protein.  B:  Truncated
CYP1B1  protein  of  93  amino  acids
(black arrow shows the position after
which  frameshift  takes  place  and  red
letters  shows  amino  acids  after
frameshift).  C:  Truncated  CYP1B1
protein of 354 amino acids.
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2933indicating that both these changes are probably damaging to
protein function. The SIFT score of p.R390H/C was 0.00 and
is predicted to be deleterious for the protein function.
The PSIC scores of the nonpathogenic single nucleotide
polymorphisms were <2 for p.R48G, p.A119S, p.N453S, and
p.L432V, indicating that all these changes were benign to
protein function. The SIFT scores of the nonpathogenic single
nucleotide polymorphisms were >0.05 for p.R48G, p.L432V,
p.K433K, and p.D449D, indicating that all these changes were
tolerated in the protein.
PCG  is  a  clinically  and  genetically  heterogeneous
disorder. More than 50 different mutations have been reported
in  the  entire  coding  region  of  CYP1B1  from  various
populations.  We  screened  the  entire  coding  region  of
CYP1B1 in 23 congenital glaucoma patients by using primers
described elsewhere [8]. Of all mutations identified herein,
the frameshift mutation (c.247delG) and nonsense mutation
(c.1063C>T) resulted in the most severe disease phenotype.
The  patient  (P55)  with  the  p.I94X  (homozygous)
mutation is a male child of a consanguineous marriage without
any family history of glaucoma; he presented at 8 months of
age.  He  was  born  at  full  term  through  a  normal  vaginal
delivery. He had severe bilateral corneal edema at birth. At
the age of 2 months he had congestion with discharge in the
left eye and was diagnosed to have a left corneal ulcer and was
treated with antibiotics; the left eye consequently developed
phthisis. The right eye dimensions increased, and he was
diagnosed as having buphthalmos at the age of 8 months.
Combined  trabeculotomy  and  trabeculectomy  with
mitomycin  C  was  performed  in  his  right  eye.  He  was
diagnosed as having 100% blindness at 8 months. His parents
were  also  screened  for  CYP1B1  mutations  by  DNA
sequencing but were found to be negative for any pathogenic
CYP1B1 mutations.
Patient P70 has a p.R355X (homozygous) mutation and
is a male offspring of a non-consanguineous marriage; he
presented at 45 days. At birth, he had bilateral congenital
Figure 8. Multi sequence alignment of
the  human  CYP1B1  protein  with  the
CYP1A1 protein from different species.
Red Underlined amino acids shows the
conserved residues in human CYP1B1
and  different  CYP1A1  protein  from
different  species  (when  mutated)
causing  primary  congenital  glaucoma
phenotype.  While  Red  letter  shows
amino  acid  conserved  in  different
CYP1A1 protein from different species
but  not  present  in  human  CYP1B1
protein.
Figure 9. Multisequence alignment of
the  human  CYP1B1  protein  with  the
CYP1B1 protein from different species.
Underlined red amino acids show the
conserved  residues  (when  mutated)
causing  the  primary  congenital
glaucoma  phenotype.  Red  colored
amino acid shows the non-conservation
of  glutamic  acid  at  this  locus  in
Zebrafish  CYP1B1.  Blue-colored
amino  acids  show  the  less  conserved
residues  in  CYP1B1  protein  from
different species.
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2934glaucoma and had IOPs of 30 and 40 mmHg in his left and
right eye, respectively. He had severe corneal clouding in both
eyes, at birth, and therefore the fundus was not visualized.
Combined  trabeculotomy  and  trabeculectomy  with
mitomycin C was performed in both eyes. He had no light
perception and was visually blind since 45 days of age. His
parents  were  also  negative  for  the  pathogenic  CYP1B1
mutations. The absence of mutations in the parents of P55 and
P70 could be due to a parental germline mutation, which
cannot be tested by using peripheral leukocytes.
Patient P56 is a female child of a non-consanguineous
marriage; she presented at the age of 1 year. She has p.Q340H
(heterozygous) and p. R390H (homozygous) mutations. She
had  bilateral  congenital  glaucoma  since  birth.  She  had  a
corneal  diameter  of  14.0×14.0  mm  (right  eye)  and
14.5×14.5 mm (left eye) and IOPs of 28 and 30 mmHg in the
right and left eye, respectively. She had Haab’s striae in both
eyes,  and  the  fundus  was  not  visible.  Combined
trabeculotomy and trabeculectomy with mitomycin C was
performed in both eyes.
Patient  P61  is  a  male  child  of  a  non-consanguineous
marriage; he presented at the age of 4 months and has a
p.H279D  (heterozygous)  mutation.  He  had  bilateral
congenital glaucoma at birth. At presentation corneal diameter
and IOPs of his left and right eye were 15.5×15.0 mm and
14.0×14.0 mm and 30 mmHg and 34 mmHg, respectively. The
cup to disc ratio of the left eye was not visible due to the hazy
media and that of the right eye was 0.9:1. He had Haab’s striae
in both eyes. Combined trabeculotomy and trabeculectomy
with mitomycin C was performed in both eyes.
An intriguing finding that apparently does not match a
typical recessive pattern of inheritance is the presence of a
heterozygous  CYP1B1  mutation  in  PCG  patients.  This
situation has been previously reported [7,29]. A heterozygous
p.Y81N mutation has also been described in PCG patients
from Germany, and a heterozygous p.E229K mutation has
been identified in unrelated French and Indian patients [7,
32]. Few heterozygous CYP1B1 mutations were associated
with the milder, primary, open-angle glaucoma phenotypes in
patients from Spain, France, and India. The presence of a
heterozygous  CYP1B1  mutation  in  PCG  suggests  the
possibility of other loci, yet undetected, that may be involved
in  anterior  chamber  formation.  Recently  the  presence  of
double heterozygote variants CYP1B1 and FOXC1 has been
described in two PCG cases, although the role of possible
digenic inheritance in disease causation is yet to be established
[33].  Defective  variants  of  modifier  genes  and/or
environmental factors have an additive effect with loss-of-
function CYP1B1 alleles to produce the disease phenotype.
However  further  work  is  required  to  understand  this
mechanism.
Previous studies have reported that the age of disease
onset in PCG patients with CYP1B1 mutations is younger than
in patients without CYP1B1 mutations [34]. Our data show
that the onset age in three patients (P60, P66, and P67) was 7,
3, and 11 months, while the rest of the patients presented at
birth. In these 20 patients there is no significant difference in
the age of disease onset in CYP1B1 mutation-positive and
mutation-negative  cases,  although  clinical  phenotypes  of
patients (P55, P56, P61, P68, and P70) with homozygous
CYP1B1 mutations were more severe compared to patients
(P64  and  P65)  who  were  heterozygous  for  the  CYP1B1
mutations (Table 1). It is possible that patients with two null
alleles with no catalytic activity may present with a more
severe phenotype of the disease compared to patients with one
null (heterozygote) allele. The disease phenotype of patients
with homozygous/heterozygous CYP1B1 mutations was more
severe compared to the clinical phenotype of patients negative
for the CYP1B1 mutations.
We  also  observed  a  higher  mean  IOP  in  a  group  of
patients with CYP1B1 mutations. In accordance with the idea
of associating the severe phenotypes with the null CYP1B1
allele, the percentage of severe phenotypes in at least one eye
has been reported to be associated with various mutations
ranging 80-100% for a frameshift mutation (e.g., c.376insA)
and  truncating  mutations  [11].  Three  different  truncation
mutations (p.C280X, p.E281X, and p.R355X) producing a
truncated  protein  of  279,  280,  and  354  amino  acids,
respectively,  have  also  been  associated  with  more  severe
disease  phenotypes  [11,21,29].  In  patient  P55  with  a
homozygous p.I94X mutation, a truncated protein of 93 amino
acids is produced that has the first 82 amino acids similar to
the wild-type CYP1B1 protein. The disease phenotype of this
patient is severe with a left phthisic and a right buphthalmic
eye with a cup to disc ratio of 0.9:1. He is visually blind.
Another patient (P70) with a p.R355X mutation had bilateral
buphthalmos  with  severe  corneal  edema  and  a  corneal
diameter of 15.0×15.0 mm and 15.0×14.5 mm in the left and
right eye, respectively. He was blind at the age of 45 days.
Patient  P61  with  a  p.H279D  mutation  had  bilateral
buphthalmos with mild edema in both eyes and a corneal
diameter of 15.5×15.5 mm and 14.0×14.0 mm in the left and
right eye, respectively. He was blind at the age of 4 months.
The range of percentages of severe phenotypes in at least one
eye  is  62–83%  for  different  mutations,  such  as  p.G61E,
p.E229K, p.R368H, and p.R390C [9].
Membrane-bound cytochromes, such as CYP1B1, have
a molecular structure containing a transmembrane domain
located at the N-terminal end of the molecule. This is followed
by a proline-rich “hinge” region, which permits flexibility
between the membrane-spanning domain and the cytoplasmic
portion of the protein molecule. The COOH-terminal ends are
highly conserved among different members of the cytochrome
P450 superfamily [17]. This family contains a set of conserved
core structures responsible for the heme-binding region of
these molecules. The heme-binding region is essential for the
normal function of every P450 molecule. Between the hinge
region and the conserved core structure lies a less conserved
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2935substrate-binding  region.  The  cytochrome  P450  protein
functions  like  any  classical  enzyme  molecule  [18,19].
Mutations  affecting  such  enzymes  generally  produce
recessive phenotypes because in heterozygous subjects the
normal allele is capable of compensating for the mutant allele.
Mutations in the CYP1B1protein interfere with the integrity
of the CYP1B1 protein as well as its ability to adopt a normal
conformation  and  to  bind  heme;  for  example,  induced
mutations in the hinge region have previously been reported
to  interfere  with  the  heme-binding  properties  of  the
cytochrome P450 molecules
Thus mutations of CYP1B1 are a major cause of PCG in
our study as well as various other studies [6-15,35-37]. This
study  confirms  genetic  heterogeneity  of  the  disease.  We
identified four novel mutations in this study in addition to one
previous reported [7]. Studies of pathogenic sequence variants
of CYP1B1 in different populations will contribute to a better
understanding of the pathogenesis of PCG and will aid in
analyzing  the  structure–function  relationship  of  different
CYP1B1 mutations Identifying mutations in subjects at risk of
developing glaucoma, particularly among relatives of PCG
patients, is of clinical significance. Monitoring vision in these
families would be helpful. These developments may help in
reducing the disease frequency in familial cases. Such studies
will also help in understanding the pathogenic mutations in
our patient populations and enable us to develop simple and
rapid diagnostic tests for analyzing such cases. This may lead
to the development of novel therapies in the management of
congenital glaucoma.
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